SCHEMBL7507641

SCHEMBL7507641

O=c1[nH]c2cc(NS(=O)(=O)c3cccs3)ccc2o1

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
BRD4 O60885 3/20 0.57
HSPD1 P10809 2/20 0.55
PTPN2 P17706 2/20 0.55
PTPN5 P54829 2/20 0.55
HSPE1 P61604 2/20 0.55
PTPN1 P18031 1/20 0.55
PKM P14618 3/20 0.53
HPGD P15428 2/20 0.53
TSHR P16473 1/20 0.53
MAPK1 P28482 1/20 0.53
HSD17B10 Q99714 1/20 0.53
MEN1 O00255 7/20 0.51
KMT2A Q03164 7/20 0.51
SMN1; SMN2 Q16637 3/20 0.51
LMNA P02545 2/20 0.51
ALDH1A1 P00352 1/20 0.51
TYMS P04818 1/20 0.51
USP2 O75604 1/20 0.51
MAPT P10636 1/20 0.48
NPSR1 Q6W5P4 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7527762 0.81 MEN1 (0.50) BRD4HPGDMEN1KMT2ASMN1; SMN2
SCHEMBL7507572 0.81 CCR2 (0.51) BRD4PKM
SCHEMBL7534508 0.81 CCR2 (0.51) BRD4PKM
SCHEMBL7507660 0.81 MEN1 (0.50) BRD4HPGDMEN1KMT2ASMN1; SMN2
SCHEMBL15479111 0.77 CCR2 (0.54) BRD4PKMMAPK1MEN1KMT2A
SCHEMBL7509034 0.77 BRD4 (0.57) BRD4PKMHPGDTSHRMAPK1
SCHEMBL28614056 0.77 HSPD1 (0.58) BRD4HSPD1PTPN2PTPN5HSPE1
SCHEMBL29031229 0.75 MEN1 (0.77) PKMHPGDTSHRMEN1KMT2A
SCHEMBL24821664 0.74 MEN1 (0.52) BRD4HSPD1PTPN2PTPN5HSPE1
SCHEMBL9931104 0.74 CCR2 (0.65) PKMMEN1KMT2ASMN1; SMN2MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20170007608-A1 ACTIVATORS OF PYRUVATE KINASE M2 AND METHODS OF TREATING DISEASE AGIOS PHARMACEUTICALS INC (US) 2017-01-12 US disclosed
US-20170007608-A1 ACTIVATORS OF PYRUVATE KINASE M2 AND METHODS OF TREATING DISEASE AGIOS PHARMACEUTICALS INC (US) 2017-01-12 US disclosed
US-20140249150-A1 ACTIVATORS OF PYRUVATE KINASE M2 AND METHODS OF TREATING DISEASE AGIOS PHARMACEUTICALS, INC (US) 2014-09-04 US disclosed
US-20140249150-A1 ACTIVATORS OF PYRUVATE KINASE M2 AND METHODS OF TREATING DISEASE AGIOS PHARMACEUTICALS, INC (US) 2014-09-04 US disclosed
US-8501953-B2 PKM2 modulators for use in the treatment of cancer AGIOS PHARMACEUTICALS, INC (US) 2013-08-06 US disclosed
US-8501953-B2 PKM2 modulators for use in the treatment of cancer AGIOS PHARMACEUTICALS, INC (US) 2013-08-06 US disclosed
US-20120122849-A1 PKM2 MODULATORS FOR USE IN THE TREATMENT OF CANCER AGIOS PHARMACEUTICALS, INC. 2012-05-17 US disclosed
US-20120122849-A1 PKM2 MODULATORS FOR USE IN THE TREATMENT OF CANCER AGIOS PHARMACEUTICALS, INC. 2012-05-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120122849-A1 PKM2 MODULATORS FOR USE IN THE TREATMENT OF CANCER PDK2, PDK1, PDK3 BRD4 881/4885HSPD1 1072/4885PTPN2 2672/4885
US-20140249150-A1 ACTIVATORS OF PYRUVATE KINASE M2 AND METHODS OF TREATING DISEASE PDK1, PC, PDK2 BRD4 1325/4885HSPD1 406/4885PTPN2 2675/4885
US-20170007608-A1 ACTIVATORS OF PYRUVATE KINASE M2 AND METHODS OF TREATING DISEASE PDK1, PC, PDK2 BRD4 1325/4885HSPD1 406/4885PTPN2 2675/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.